Are regenerative injections an option for my pain now?

Ongoing joint or tendon pain often reaches a frustrating stage: physiotherapy has been tried, activity has been modified, and tablets or a standard injection may have given only partial relief. At that point, “regenerative injections” such as PRP, microfragmented fat (mFAT/Lipogems) or bone-marrow concentrate (BMAC) are often raised as a next-step option—usually aimed at improving pain and function for months rather than offering a guaranteed cure.

These treatments are part of a group often called orthobiologics: autologous products prepared from the patient and then placed accurately with an ultrasound-guided injection. PRP is made from a blood sample and concentrates platelets and their growth factors, which are used in many chronic tendon problems and in mild–moderate osteoarthritis. Microfragmented fat is prepared from a small fat harvest and re-injected as minimally processed adipose tissue, and BMAC is produced from a bone-marrow draw (most commonly from the pelvis) before being injected; both are generally discussed as “biologic support” for joints where cartilage and subchondral bone are part of the problem, rather than as a way to “regrow a new joint”. Across reviews, the best fit tends to be earlier-stage osteoarthritis, focal cartilage problems, or chronic tendinopathy—not established “bone-on-bone” arthritis. Serious complications are reported rarely in published series, with short-lived post-injection soreness and swelling being more typical.

The evidence picture is mixed. PRP has the broadest set of controlled trials across osteoarthritis and tendinopathy, with consistent symptom improvements reported in several joints, including hip osteoarthritis in randomised ultrasound-guided studies with follow-up out to 6–12 months. For mFAT and BMAC, there are encouraging cohorts and some randomised data, but the overall certainty remains lower and protocols vary between studies. A 2025 systematic review and meta-analysis in symptomatic knee osteoarthritis found mFAT was not statistically superior to other injectables—PRP, BMAC, hyaluronic acid or corticosteroid—on pain (VAS) or KOOS outcomes at 3, 6 or 12 months, and rated the certainty of evidence as low.

Corticosteroid (“steroid”) injections remain a legitimate tool in 2024–2025 practice, particularly when fast symptom control matters. In chronic lateral epicondylitis (tennis elbow), higher-level reviews and RCT meta-analysis show a clear timing trade-off: steroid tends to do better in the first 2–6 weeks, but the advantage often fades by around 3 months, while PRP is slower to take effect and more likely to look better at 6–12 months. That difference in time-course is one reason biologic injections are often discussed when the aim is longer-lasting improvement rather than rapid, short-term relief.

The sections that follow break this down by problem area—what tends to suit PRP, where fat or marrow injections may make more sense, and where expectations need to be kept firmly realistic based on the current trial data.

Who might benefit from microfragmented fat injections in knees or hips?

Microfragmented fat (often referred to by device names such as Lipogems) tends to be considered when knee or hip osteoarthritis is still at an earlier stage, symptoms are persistent despite a structured course of conservative care, and the aim is longer-lasting improvement in pain and day-to-day function rather than a quick flare-settling injection. In published knee cohorts, the signal has been strongest in people with mild/early osteoarthritis rather than established “bone-on-bone” change. [4, 5]

The practical pathway is usually a single outpatient visit: a small amount of the patient’s own fat is taken using a needle-based harvest under local anaesthetic (commonly from the abdomen or thigh), processed in a closed system into microfragmented fat, and then placed into the painful joint with an ultrasound-guided injection in the same session. Because it is the patient’s own tissue, the safety profile reported in these series is mostly short-lived post-injection soreness and swelling rather than serious complications. [4, 5]

For knees, two prospective open-label studies (including 17 patients/32 knees, with follow-up reported out to 24 months) describe clinically meaningful improvements in pain and function after a single intra-articular microfragmented fat injection. They also reported MRI findings (using dGEMRIC) that were consistent with improved cartilage “composition signals” in some regions—best seen as a hint that the joint environment may be shifting in a healthier direction in some cases, rather than proof that cartilage has been “regrown”. [4, 5]

Patient selection matters. In a multicentre cohort of 91 people with early/mild knee osteoarthritis, age over 60 and the presence of synovitis (a more inflamed joint lining) predicted worse pain outcomes at 1 year, while BMI and focal-versus-diffuse wear patterns did not. In other words, the best-fit profile in this dataset was a relatively younger patient with a “quieter” knee, even if the MRI shows cartilage wear. [6]

More advanced knees need more caution.

For hips, an observational series of 147 patients reported significant 1-year improvements in pain and Oxford Hip Score after intra-articular microfragmented fat, and adding PRP did not show a clear extra advantage in that study. This study also reflects a practical point: treating two large joints (for example both hips) from a single fat harvest can be feasible, and knee studies have similarly treated both knees in one session; the processed fat is divided under sterile conditions rather than the same syringe being moved between joints. [7, 4]

Expectations still need to be grounded against other injectables. A 2025 systematic review and meta-analysis in symptomatic knee osteoarthritis found microfragmented fat was not statistically superior to PRP, BMAC, hyaluronic acid, or corticosteroid injections for pain (VAS) or KOOS outcomes at 3, 6, or 12 months, with low certainty of evidence—so it is best seen as one reasonable option in the menu, not an automatic upgrade. [1]

Where does bone-marrow concentrate fit for cartilage damage?

Bone‑marrow aspirate concentrate (BMAC) tends to make the most sense when the problem is a discrete cartilage defect rather than general “wear and tear”. In earlier drafts, internal reference codes were shown in the text; here the same evidence is summarised in plain language without those codes.

BMAC starts with a small draw of bone marrow, most often from the pelvic bone (iliac crest) using local anaesthetic, then the sample is processed to concentrate a marrow “fraction” that contains progenitor cells and signalling proteins (growth factors). In clinic pathways it may be re‑injected under ultrasound guidance, but much of the published knee evidence is actually built around targeted cartilage-repair procedures where BMAC is delivered directly to the damaged area during an operative repair.

Knee: mainly a cartilage‑repair adjunct, not a generic joint injection

In the knee, the strongest theme across reports is single‑stage structural repair: BMAC is used as an adjunct during operative cartilage repair (for example, delivered on or with a scaffold-based repair construct). Across these reports, patient‑reported outcomes such as KOOS commonly improve and MRI often shows “fill”/repair features of the defect at follow‑up points reported between around 1 and 5 years.

A matched cohort study found broadly similar symptom improvement at 1 year between HA‑BMAC and minced cartilage transplantation, but MRI repair quality (MOCART‑2) slightly favoured the minced cartilage approach—reinforcing that BMAC in this setting is being used to support repair tissue quality, not to guarantee cartilage restoration.

Typical “best‑fit” knee profiles described in this literature are younger, active patients with a focal full‑thickness lesion (often from injury) who are aiming to avoid or defer bigger reconstructive options such as osteochondral grafting. Because these are repair‑style pathways, they usually come with a more demanding rehabilitation plan than a simple pain‑relief injection (for example, structured physiotherapy and activity restriction tailored to the defect and procedure).

PRP hip injections under ultrasound guidance versus cortisone

Hip osteoarthritis pain is often felt in the groin, the outside of the hip or the buttock, and it commonly becomes a problem when walking distance, sleep or work has started to suffer. PRP is most often discussed for mild to moderate hip arthritis (typically grade 2–3 on common X‑ray scales) when exercise-based rehab and simple pain relief have not been enough, but the joint is not yet at the “hip replacement now” stage. In this section the hip evidence is summarised from published trials and reviews without embedding raw citation strings in the prose.

In the hip, the best direct evidence for PRP comes from randomised, ultrasound‑guided injection trials that use PRP as a benchmark against hyaluronic acid (HA), rather than against cortisone. In published RCTs summarised in systematic reviews, a course of ultrasound‑guided intra‑articular PRP injections has produced improvements in pain and hip scores at 6 and 12 months, with results broadly similar to HA in some comparisons. A later 105‑patient trial (grade 2–3 OA) found that two ultrasound‑guided injections of PRP (or PRP+HA) led to greater 6‑month improvements in WOMAC and Lequesne scores than HA alone. A 2024 systematic review of five hip RCTs concluded PRP appears safe and can improve pain and function for many people over roughly 6–12 months, although PRP preparation methods vary between studies.

By contrast, there are currently no randomised trials in hip OA that directly compare PRP with corticosteroid. That matters, because it means hip decisions are usually made using (1) hip PRP versus HA data, and (2) the typical steroid pattern seen in other body areas. In lateral epicondylitis (“tennis elbow”), a review of systematic reviews reported that corticosteroid tends to produce stronger early relief over about 2–6 weeks, but benefit often diminishes by around 3 months, while PRP has a slower onset and better longer‑term outcomes.

Put into a practical “which option fits the goal?” summary (recognising the hip has its own biology and evidence gaps):

• PRP may fit best when the priority is a more sustained improvement over months (often building over several weeks), and when avoiding repeated steroid exposure is a key concern; hip trials report few major adverse events and mainly short‑lived post‑injection soreness.
• A one‑off cortisone injection may fit best when rapid symptom settling is the main aim (for example, a flare that is limiting walking or sleep), with the understanding that the effect is often time‑limited in many injection studies from other joints.

Even with the more encouraging hip PRP trials, there is still no strong evidence that PRP reliably alters the long‑term likelihood or timing of hip replacement.

PRP or steroid for stubborn tennis elbow and golfer’s elbow?

When elbow pain has dragged on for 3–6 months, the issue is often less about a “simple inflammation” and more about a tendon that has become irritated and sensitive at its attachment point. Tennis elbow is pain on the outside of the elbow (lateral epicondylitis), while golfer’s elbow is similar pain on the inside (medial epicondylitis). Either can flare with gripping, lifting a kettle, or repetitive mouse and keyboard work.

The clearest head-to-head evidence is for tennis elbow. A systematic review of systematic reviews and a separate meta-analysis of randomised trials both found a consistent pattern: corticosteroid injections tend to give stronger early symptom relief, but that advantage commonly fades by about the 3‑month mark, while PRP tends to build more gradually and is more likely to look better at longer follow-up points such as 6–12 months. In other words, steroid is usually the faster “calm it down” option; PRP is more often used with a longer-view aim of improving pain and function over time rather than just switching symptoms off. [3]

Individual trials broadly echo that timing trade-off. In a 120‑patient randomised study of chronic lateral epicondylitis, the steroid group did best at 2 and 4 weeks, but by 6 months PRP (and autologous blood) were better than steroid on pain and function scores. A smaller 40‑patient trial also reported steroids performing better early (around 4–8 weeks) but PRP pulling ahead by 12–24 weeks, with steroid benefits more likely to plateau. [12, 13]

For golfer’s elbow, the evidence base is thinner than for tennis elbow, so the PRP-versus-steroid discussion is often an extrapolation from lateral epicondylitis data rather than a like-for-like set of medial-elbow trials.

The two injections also differ in what the appointment involves:

• Steroid is usually a single, quick injection aimed at damping down an inflammatory pain cycle around the tendon origin.
• PRP involves taking a blood sample on the day, processing it to concentrate platelets, then injecting the PRP into the painful tendon origin—often under ultrasound guidance to target the degenerative area rather than simply the nearby joint space.

Common “how it plays out” scenarios include a manual worker with a fixed deadline in the next 2–4 weeks (where rapid, time-limited relief may be the priority) versus a recreational golfer or tennis player trying to avoid recurring flare-ups over the next season (where slower improvement with better durability is often the goal).

Where do PRP shoulder injections sit between physio, steroid and surgery?

Night pain, a painful “catch” when reaching overhead, or a shoulder that will not tolerate sport after a proper rehab programme often points to rotator cuff–related pain (typically tendinopathy or a partial‑thickness tear) rather than a simple one‑off strain. This is the group in which injections tend to be discussed: symptoms that have persisted despite structured physiotherapy, sometimes after a single corticosteroid injection has only partly helped.

One of the clearest summaries comes from a 2025 meta‑analysis of 15 randomised controlled trials (n≈2,761) comparing platelet‑rich plasma (PRP) with corticosteroid for rotator cuff tendinopathy. Across studies there were no significant differences in function at 3–15 weeks, but PRP showed significantly better functional scores at 16–24 weeks. Pain outcomes tended to favour steroid early (non‑significantly) and trend towards PRP later, which fits the idea that PRP is less of a “switch it off this fortnight” treatment and more of a medium‑term option. [14]

Longer follow‑up data across studies are mixed rather than one‑sided, so PRP should be discussed as a reasonable alternative (and in some analyses an intermediate-term functional advantage) rather than a guaranteed upgrade on steroid. [14]

The “where does it sit?” question is also about tendon biology. A 2026 narrative review of chronic rotator cuff tendinopathy concluded that NSAIDs and corticosteroid injections mainly provide short‑lived symptom relief and, when repeated, may impair tendon health, whereas PRP and other regenerative biologics more often show better intermediate‑ and longer‑term pain and functional outcomes. That places PRP most naturally as a second‑line step after good physiotherapy, and before escalation to operative repair in selected cases. [15]

Injection technique matters in the shoulder. Rotator cuff–related injections are usually aimed into the subacromial space or around the tendon rather than simply “into the joint”, so ultrasound guidance is often used in MSK practice to place PRP or steroid at the intended target and to avoid nearby structures.

Steroid still has a role in 2025 care pathways, particularly for an inflammatory flare that is blocking sleep or rehab, but the trade‑off is that the benefit can be time‑limited and repeated dosing is the scenario that raises more tendon‑health concern. PRP involves a blood draw and can bring a short‑term soreness flare, but the best evidence suggests any advantage—when it appears—tends to show up over the months rather than the first few weeks; the closing point here is the clinical fit, not booking logistics.

1. [1] Microfragmented Adipose Tissue Has No Advantage Over Platelet-Rich Plasma and Bone Marrow Aspirate Injections for Symptomatic Knee Osteoarthritis: A Systematic Review and Meta-analysis. (2025). https://doi.org/10.1177/03635465241249940 https://doi.org/10.1177/03635465241249940